These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 17534875)

  • 1. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Park YH; Lee SY; Lee JS
    Lung Cancer; 2009 Jan; 63(1):115-20. PubMed ID: 18221820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis.
    Campa D; Müller P; Edler L; Knoefel L; Barale R; Heussel CP; Thomas M; Canzian F; Risch A
    Int J Cancer; 2012 Dec; 131(12):2920-8. PubMed ID: 22473764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Kim HT; Lee JS
    Lung Cancer; 2008 Jan; 59(1):69-75. PubMed ID: 17766002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan pathway genotype analysis to predict pharmacokinetics.
    Mathijssen RH; Marsh S; Karlsson MO; Xie R; Baker SD; Verweij J; Sparreboom A; McLeod HL
    Clin Cancer Res; 2003 Aug; 9(9):3246-53. PubMed ID: 12960109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
    Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Matsunaga M; Araki K; Tanaka R; Ichikawa W; Miya T; Narabayashi M; Akiyama Y; Kawara K; Ando Y; Sasaki Y
    Biol Pharm Bull; 2008 Nov; 31(11):2137-42. PubMed ID: 18981587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
    Atasilp C; Chansriwong P; Sirachainan E; Reungwetwattana T; Sirilerttrakul S; Chamnanphon M; Puangpetch A; Sukasem C
    Sci Rep; 2020 Aug; 10(1):13486. PubMed ID: 32778670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.
    Chen S; Villeneuve L; Jonker D; Couture F; Laverdière I; Cecchin E; Innocenti F; Toffoli G; Lévesque E; Guillemette C
    Pharmacogenet Genomics; 2015 Dec; 25(12):573-83. PubMed ID: 26352872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
    Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
    Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Correlation of MDR1 and ABCG2 genetic polymorphisms with the efficacy and adverse events of irinotecan chemotherapy in patients with colorectal cancer].
    Sun ZW; Wang XC; Gao J; Li J; Li YY; Dang YZ; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Jun; 16(6):524-8. PubMed ID: 23801203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
    Akamine Y; Miura M; Sunagawa S; Kagaya H; Yasui-Furukori N; Uno T
    Xenobiotica; 2010 Nov; 40(11):782-9. PubMed ID: 20839930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
    Zamboni WC; Ramanathan RK; McLeod HL; Mani S; Potter DM; Strychor S; Maruca LJ; King CR; Jung LL; Parise RA; Egorin MJ; Davis TA; Marsh S
    Invest New Drugs; 2006 Sep; 24(5):393-401. PubMed ID: 16505951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients.
    Jada SR; Lim R; Wong CI; Shu X; Lee SC; Zhou Q; Goh BC; Chowbay B
    Cancer Sci; 2007 Sep; 98(9):1461-7. PubMed ID: 17627617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic interaction of ABCB1 and ABCG2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy.
    Erdilyi DJ; Kámory E; Csókay B; Andrikovics H; Tordai A; Kiss C; Filni-Semsei A; Janszky I; Zalka A; Fekete G; Falus A; Kovács GT; Szalai C
    Pharmacogenomics J; 2008 Oct; 8(5):321-7. PubMed ID: 17938643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
    Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
    J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
    Innocenti F; Kroetz DL; Schuetz E; Dolan ME; Ramírez J; Relling M; Chen P; Das S; Rosner GL; Ratain MJ
    J Clin Oncol; 2009 Jun; 27(16):2604-14. PubMed ID: 19349540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
    de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
    Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.
    de Jong FA; Marsh S; Mathijssen RH; King C; Verweij J; Sparreboom A; McLeod HL
    Clin Cancer Res; 2004 Sep; 10(17):5889-94. PubMed ID: 15355921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients.
    Qu J; Zhou BT; Yin JY; Xu XJ; Zhao YC; Lei GH; Tang Q; Zhou HH; Liu ZQ
    CNS Neurosci Ther; 2012 Aug; 18(8):647-51. PubMed ID: 22630058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.